Startups & Venture

Biomatter Raises $18M to Design Custom Enzymes With AI

By mohitdeep1122 • • 6 min read • 📷 3 High-Res Visuals
Share Dispatch
𝕏 Post in Share Y Hacker News
⚡ TL;DR — Executive Summary

Most enzyme engineering starts with a protein that already exists in nature and attempts to improve it. Biomatter wants to reverse that process: start with the chemical reaction a manufacturer needs and use AI to design an enzyme capable of performing it. This could change how pharmaceutical ingredients, diagnostic products, food ingredients and industrial chemicals are manufactured.

Biomatter raises $18 million in Series A funding to advance AI-designed enzymes and expand its industrial biotechnology platform.
Biomatter raises $18 million in Series A funding to advance AI-designed enzymes and expand its industrial biotechnology platform. 🔍 Click to zoom

Enzymes are among the most important biological tools used in modern industry. They accelerate chemical reactions involved in manufacturing medicines, food ingredients, laboratory reagents and industrial materials. However, conventional enzyme engineering often starts with a protein that already exists in nature and modifies it to improve performance. That approach can take months or even years, particularly when the required chemical reaction is difficult or the natural enzyme is poorly suited to the task. Vilnius-based Biomatter wants to change this process using artificial intelligence. The biotechnology company has raised an oversubscribed $18 million Series A, equivalent to approximately €16.2 million, led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet. Its ambition is to design custom enzymes directly from the chemistry a customer needs, including functions that existing natural enzymes cannot perform efficiently.

Biomatter uses its Intelligent Architecture platform to design custom protein structures and enzymes for specialised industrial applications.
Biomatter uses its Intelligent Architecture platform to design custom protein structures and enzymes for specialised industrial applications.🔍 Click image to enlarge

Instead of modifying nature, Biomatter designs enzymes from the required chemical reaction

Most traditional enzyme development begins with identifying a natural protein that performs a similar function to the desired reaction. Scientists then make changes to its amino acid sequence, test the resulting protein and repeat the process until they achieve the required activity, stability and production characteristics. Biomatter follows a different approach. A customer first defines the chemical transformation needed for a product or manufacturing process. Its Intelligent Architecture platform then uses computational models to design protein sequences and structures around that target. Rather than being restricted to small modifications of an existing natural enzyme, the system aims to explore much larger changes in protein sequence and structure. This creates an opportunity to develop catalysts for reactions that conventional biological engineering struggles to support. Every proposed design still undergoes laboratory testing before it is delivered, because a computationally promising protein must demonstrate real chemical activity to become commercially useful.

Intelligent Architecture combines generative AI, physics and experimental biology

The foundation of Biomatter’s technology is Intelligent Architecture, a proprietary platform that combines data-driven generative AI with physics-based computational methods. Protein design is difficult because a protein’s amino acid sequence influences how it folds into a three-dimensional structure, and that structure determines how it interacts with other molecules. A small change can affect activity, stability, temperature tolerance and production yield. Biomatter uses its computational models to explore possible designs, while physics-based methods help evaluate whether those structures could perform the intended function. The company has also invested years in generating its own experimentally characterised enzyme data rather than relying exclusively on naturally occurring protein databases. Each completed development programme adds new experimental results to this dataset, giving future design projects more information to work with. The combination of computational design and physical validation is central to its attempt to make custom enzyme engineering faster and more predictable.

Its technology is already reaching commercial products, not just research laboratories

One important indication of Biomatter’s commercial progress is its collaboration with Thermo Fisher Scientific on Invitrogen SuperScript V Reverse Transcriptase. This enzyme converts RNA into complementary DNA, a process widely used in molecular biology laboratories and mRNA research. Biomatter worked with Thermo Fisher to improve the enzyme’s resistance to oxidation, contributing to the product’s reagent stability. SuperScript V is designed to support ambient-temperature shipping and room-temperature storage of the standalone enzyme for up to six months, according to Thermo Fisher’s product information. The distinction matters because the collaboration connects AI-designed protein engineering to a product sold by an established global scientific equipment and life-sciences company. Biomatter also reports developing a methylase for mRNA vaccine manufacturing that works without S-adenosylmethionine, or SAM, an expensive chemical component normally required by natural versions of the enzyme. That programme illustrates how designing from the target reaction could potentially remove requirements that traditional enzymes cannot easily avoid.

AI-designed enzymes could help pharmaceutical, food and chemical manufacturers develop more efficient biological production processes.
AI-designed enzymes could help pharmaceutical, food and chemical manufacturers develop more efficient biological production processes.🔍 Click image to enlarge

More than 50 custom enzymes and 25 enterprise customers provide early validation

Biomatter says it has delivered more than 50 custom enzymes to over 25 enterprise customers across Europe, the United States and Japan. Its announced customer relationships include AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos, spanning pharmaceutical development, diagnostics, agriculture, food and industrial biotechnology. These companies have different requirements, but they share a need for enzymes that operate reliably under specific production conditions. A pharmaceutical manufacturer might need improved stability, while a food ingredients company could need a catalyst that produces a particular compound more efficiently. Biomatter says several customer relationships have expanded from individual projects into multi-year programmes involving multiple enzymes. This repeat business is particularly important because industrial biotechnology customers must validate new processes carefully before incorporating them into commercial manufacturing. The company is therefore developing a business based on delivering custom biological components for existing products and future industrial processes rather than simply licensing an AI research tool.

The €16.2M expansion will bring AI design and laboratory testing closer together

The new financing will fund a 2,000-square-metre enzyme design and testing facility in Vilnius, scheduled to open in 2027. The facility will bring more computational design, experimental validation and iteration under one roof. Biomatter says its current development programmes take weeks, compared with months or years for many conventional enzyme engineering projects, and it wants to shorten that process to days. Faster testing matters because AI-generated designs only become valuable when their actual performance can be measured and fed back into subsequent iterations. The company will also expand its commercial team and strengthen its presence in the United States, where approximately half of its customers are based. A larger laboratory and more integrated experimental workflow could allow it to handle more customer projects simultaneously while increasing the amount of proprietary enzyme data generated through its work. The financing will also support continued investment in the computational platform itself.

Why AI-designed enzymes could transform manufacturing beyond pharmaceuticals

The opportunity extends well beyond drug discovery. Enzymes are used in food processing, agricultural chemicals, detergents, diagnostics, bio-based materials and industrial chemical manufacturing. Manufacturers are increasingly interested in biological processes because enzymes can perform specific chemical transformations under conditions that may be less energy-intensive than conventional industrial chemistry. However, naturally occurring enzymes do not always have the activity, stability or selectivity needed for a commercial process. Biomatter’s approach could help companies design catalysts around their actual production requirements rather than redesigning their products around the limitations of available biological tools. Its technology could also support the development of new ingredients and materials that are difficult to produce through existing manufacturing methods. The key commercial advantage would be the ability to repeatedly design, validate and supply enzymes that solve specific industrial problems, although each application will still require its own technical, safety and manufacturing validation.

Biomatter wants to make custom enzymes as accessible as standard industrial ingredients

Founded in 2018 by a team originating from Vilnius University’s life sciences research community, Biomatter is attempting to turn advanced protein engineering into a more accessible industrial service. Its long-term vision is to make ordering a custom enzyme as straightforward as ordering a standard catalogue reagent, even when the required function does not yet exist in nature. That ambition will depend on more than model quality: the company must consistently achieve successful laboratory validation, scalable production, commercial pricing and regulatory acceptance across different industries. Competition in AI-driven protein design is also increasing as more companies explore generative models for biological molecules. Biomatter’s advantage will need to come from the combination of its proprietary experimental dataset, computational architecture, industrial customer relationships and ability to deliver working enzymes. Its $18 million Series A provides the resources to expand those capabilities. If it succeeds, the company could help shift industrial biotechnology from improving what nature already provides towards designing biological catalysts around what manufacturers actually need.

Sources and further reading

📷 Complete Article Visual Gallery (3 Pictures) Click any photo for full-screen view
Biomatter raises $18 million in Series A funding to advance AI-designed enzymes and expand its industrial biotechnology platform.
Biomatter raises $18 million in Series A funding to advance AI-designed enzymes and expand its industrial biotechnology platform.
Biomatter uses its Intelligent Architecture platform to design custom protein structures and enzymes for specialised industrial applications.
Biomatter uses its Intelligent Architecture platform to design custom protein structures and enzymes for specialised industrial applications.
AI-designed enzymes could help pharmaceutical, food and chemical manufacturers develop more efficient biological production processes.
AI-designed enzymes could help pharmaceutical, food and chemical manufacturers develop more efficient biological production processes.
mohitdeep1122 • TechFront360 Editorial Desk

Published by TechFront360.com following our strict fact-checking, benchmark verification, and independent technology journalism standards.

More in Startups & Venture